Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OptiNose presents fluticasone study results
The results showed that administering fluticasone with OptiNose’s device is effective in the treatment of refractory CRS, with significant and clinically relevant improvements compared with placebo in both
The results showed that administering fluticasone with OptiNose’s device is effective in the treatment of refractory CRS, with significant and clinically relevant improvements compared with placebo in both
Let-7 was the first miRNA that was demonstrated to function as a tumor suppressor via its ability to regulate oncogene expression, Mirna Therapeutics said. Mirna Therapeutics said that
iGPS claimed that the new service iGPS bios provides a level of pallet hygiene and security that cannot be achieved with pallets made of wood or other organic
EraMune 01 is designed and sponsored by the French not-for-profit institution Objectif Recherche VACcin Sida (ORVACS) with financial support from the Bettencourt-Schueller Foundation, Paris, France. EraMune 01 main
Azilsartan medoxomil is a prodrug of the active moiety azilsartan, which lowers blood pressure by blocking the action of a vasopressor hormone, angiotensin II, Takeda said. Azilsartan medoxomil
Salix Pharma and Norway-based specialty pharmaceutical company Photocure have entered into an agreement under which the two companies will collaborate in the development and commercialisation of Lumacan. Lumacan
Pradaxa is an anticoagulant that acts by inhibiting thrombin, an enzyme in the blood that is involved in blood clotting. A clinical trial comparing with the anticoagulant warfarin
The INOVA H3-5 syringe line operates within a Restricted Access Barrier System (RABS) and incorporates the ability to fill under vacuum, which facilitates handling of viscous products and
MKC1106-MT is an active immunotherapeutic treatment consisting of three components, a DNA plasmid encoding select portions of Melan A and tyrosinase (two tumor-specific antigens that are highly expressed
According to ImmuPharma, the study was designed to show safety and tolerability and assess the maximum tolerated dose of IPP-204106. In the trial, the patients were dosed with